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ABSTRACT
Sodium-glucose co-transporter 2 (SGLT2) inhi-
bitors are an attractive novel therapeutic option
for the treatment of type 2 diabetes. They block
the reabsorption of filtered glucose in kidneys,
mainly in proximal renal tubules, resulting in
increased urinary glucose excretion and
correction of the diabetes-related hyper-
glycemia. Beyond improving glucose control,
SGLT2 inhibitors offer potential benefits by
reducing body weight and blood pressure. On
the basis of the efficacy demonstrated in clinical
trials, SGLT2 inhibitors are recommended as
second- or third-line agents for the manage-
ment of patients with type 2 diabetes. Beneficial
effects on kidney disease progression, cardio-
vascular and all-cause mortality, and hospital-
ization for heart failure have also been
demonstrated with one SGLT2 inhibitor (em-
pagliflozin). Potential adverse events resulting
from their mechanism of action or related to
concomitant therapies are reviewed. A treat-
ment algorithm for the adjustment of
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concomitant therapies after initiating SGLT2
inhibitors is also proposed.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
metabolic condition characterized by a hyper-
glycemic state due to impaired insulin secretion
and diminished insulin action in peripheral
tissues [1]. Diabetes is the leading cause of
blindness, non-traumatic limb amputations,
and chronic kidney disease. It is strongly asso-
ciated with an increased risk of life-threatening
cardiovascular complications, such as myocar-
dial infarction or stroke. Achieving optimal
glycemic control remains a challenge due to
several obstacles: the pathophysiology of dia-
betes, involving multiple deficiencies and/or
resistances; low treatment adherence; clinical
inertia; and resistance to implementing behav-
ioral and lifestyle changes [2]. Adverse events
(AEs), such as hypoglycemia or weight gain, also
contribute to the challenge [3]. Traditional
therapeutic approaches have been characterized
by stimulating insulin secretion and/or
improving peripheral insulin resistance.
Sodium-glucose co-transporter 2 (SGLT2) inhi-
bitors (dapagliflozin, canagliflozin, and empa-
gliflozin in the USA and Europe, and
ipragliflozin, luseogliflozin, and tofogliflozin in
Japan) are a novel and attractive therapeutic
approach for the treatment of T2DM [4].
PHYSIOLOGICAL ACTION OF SGLT2
INHIBITORS
SGLT2 inhibitors treat T2DM by selectively
blocking SGLT2, a high capacity and low affin-
ity glucose transporter expressed mainly in the
S1 and S2 segments of the proximal tubule,
inhibiting glucose reabsorption, lowering the
renal glucose threshold, and inducing urinary
glucose elimination (Fig. 1) [5]. SGLT2 activity
seems to be upregulated in patients with T2DM,
thereby increasing the renal glucose threshold
and exacerbating the tendency to hyper-
glycemia. Inhibiting SGLT2 activity is accom-
panied by glycosuria and osmotic diuresis.
Despite the fact that SGLT2 activity accounts for
up to 90% of renal glucose reabsorption, in
clinical practice SGLT2 inhibitors only block
30–50% of the filtered glucose load, even at
higher doses [6]. An excess of 40–80 g of glucose
and 200–600 mL urine per day are reported with
the chronic administration of SGLT2 inhibitors
[6]. Dosing and glomerular filtration rate cutoffs
for SGLT2 inhibitors are shown in Table 1. The
therapeutically induced glycosuria and osmotic
diuresis lead to reductions in plasma glucose,
body weight, and systolic and diastolic blood
pressure [7]. These collateral effects are poten-
tially beneficial because they may reduce the
development of microvascular and macrovas-
cular complications. On the basis of the efficacy
demonstrated in clinical trials, SGLT2 inhibitors
are recommended as second- or third-line
agents for the management of patients with
T2DM [8]. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects per-
formed by any of the authors.
CLINICAL EFFICACY
In randomized phase 2 and 3 clinical trials, the
use of SGLT2 inhibitors as monotherapy (only
indicated when intolerance to metformin or
side effects exist) has been shown to signifi-
cantly improve glycemic control in patients
with T2DM. A systematic review of 45 ran-
domized clinical studies comparing SGLT2
inhibitors to placebo (11,232 patients impli-
cated) and 13 studies comparing SGLT2 inhibi-
tors to active comparators (5175 patients using
metformin, sitagliptin, or sulfonylurea) repor-
ted a reduction in HbA1c of -0.66% (95%
confidence interval (CI) -0.73% to -0.58%)
compared with placebo and -0.06% (95% CI
-0.18% to 0.05%) with respect to active com-
parators [7]. Greater HbA1c reductions (0.44%,
0.54%, and 1.01%) have been observed in
patients with high baseline HbA1c levels, i.e.,
HbA1c less than 8.0% (64 mmol/mol),
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HbA1c = 8.0–9.0% (64–75 mmol/mol), and
HbA1c greater than 9.0% (75 mmol/mol),
respectively [9]. In addition, SGLT2 inhibitor
therapy as monotherapy or in combination
with metformin has been described to induce
stable weight loss [10, 11]. In a systematic
review, in comparison with other agents, SGLT2
inhibitors reduced mean body weight by
-1.80 kg (95% CI -3.50 to -0.11 kg) [7]. In this
vein, SGLT2 inhibitors have also been associ-
ated with a reduced systolic blood pressure of
-4.45 mmHg (95% CI -5.73 to -3.18 mmHg)
from baseline. A meta-analysis involving 27
randomized clinical trials and 12,960 individu-
als (follow-up period ranging from 4 to
52 weeks) recently demonstrated that SGLT2
inhibitors achieve a reduction of systolic and
diastolic blood pressure of -4.0 and
-1.6 mmHg, respectively [12]. Finally, the
EMPA-REG OUTCOME trial, which aimed to
evaluate long-term effects of empagliflozin on
renal and cardiovascular outcomes in T2DM
patients (3.1 years of median follow-up period),
has demonstrated that, in addition to standard
care, empagliflozin reduced the rate of incident
or worsening nephropathy (approximately 39%
reduction), serum creatinine doubling (44%),
initiation of renal replacement therapy (55%),
the risk of death from cardiovascular disease
(38%), hospitalization for heart failure (35%),
and all-cause death (32%) in patients with
T2DM and high cardiovascular risk [13, 14].
Separation of event curves started very early in
the study and is a matter of debate. The mech-
anisms involved in cardiovascular and renal
benefits of empagliflozin are multifactorial.
Hemodynamic effects, specifically reduced
blood pressure and extracellular volume, driven
by the direct drug class mechanism of action
(osmotic diuresis), seems to be the main expla-
nation for such a rapid effect, especially applied
to the reduction in cardiovascular mortality and
heart failure-related events. Many other factors
including changes in weight, cardiac function,
and metabolic actions could also be implied. A
possible class effect should be confirmed in
upcoming cardiovascular outcomes trials using
other SGLT2 inhibitors.
Fig. 1 Renal hyperfiltration in type 2 diabetes patients and the impact of receiving SGLT2 inhibitors. Modified from
Fioretto et al. [5]. SGLT2 sodium-glucose co-transporter 2
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ADVERSE EVENTS ASSOCIATED
WITH SGLT2 AND CONCOMITANT
THERAPIES
The overall incidence of AEs using dapagli-
flozin, canagliflozin, or empagliflozin varies
between 57.3% and 83.0% in different clinical
trials, which is similar to other antidiabetic
drugs (e.g., with metformin it ranges between
36.6% and 81.0%) [15]. Most frequent AEs are
infections of the genitourinary tract (including
vulvovaginitis in women or balanitis in men),
with a frequency between 3.6% and 9.0%.
Patients usually experience only a single epi-
sode, mild in intensity, and that responds to
standard treatment [4].
SGLT2 inhibitors, when used in monother-
apy, are associated with a low risk of hypo-
glycemia owing to their insulin-independent
mechanism of action [7]. Additionally, long-
term use of SGLT2 inhibitors has been associ-
ated with a rise in plasma glucagon levels and
increased hepatic glucose production [16].
Interestingly, SGLT2-induced glucagon secre-
tion is prevented by administering sulfony-
lureas concomitantly, thus explaining the risk
of hypoglycemia with the use of these agents
[11, 17–19]. The frequency of hypoglycemia
increases significantly when SGLT2 inhibitors
are used with a background therapy that
includes sulfonylureas [11, 17–19] or insulin
[20–23], compared to placebo. Reported fre-
quencies of hypoglycemia using SGLT2 inhibi-
tors vary greatly, from 6.9% [11] to 43.2% [12]
with sulfonylureas, and from 29.2% [20] to
60.4% [21] with insulin. AEs are more likely to
occur during the first few days or weeks of
treatment [24].
Reducing the insulin dose has also been
associated with euglycemic diabetic ketoacido-
sis [25]. The US Food and Drug Administration
(FDA) issued a warning in May 2015 about the
potential risk of diabetic ketoacidosis in patients
receiving SGLT2 inhibitors and, in February
2016, the European Medicines Agency (EMA)
established recommendations to reduce the risk
of diabetic ketoacidosis reported in these
patients [26, 27]. Nevertheless, the warning and
recommendations come from case series with
few patients, mainly those with type 1 diabetes
who are insulin deficient [28]. To date, the cause
of the higher frequency of diabetic ketoacidosis
Table 1 Dosing and glomerular filtration rate cutoffs for SGLT2 inhibitors
SGLT2 inhibitor Dose (mg) Glomerular filtration rate
cutoffs (mL/min/1.73 m2)
Recommendation
Dapagliflozin 5 [60 No dose adjustment
10a \60 Initial use is not recommended
Discontinue in patients already on treatment
\30 Contraindicated
Canagliflozin 100 \30 Avoid
300 45–60 Use 100 mg dosing
\45 Discontinue in patients already on treatment
30–45 Initial use is not recommended
Empagliflozin 10 C45 No dose adjustment
25 \45 Initial use is not recommended
Discontinue in patients already on treatment
\30 Contraindicated
a In Europe dapagliflozin has only been commercialized as a dose of 10 mg
956 Diabetes Ther (2017) 8:953–962
in patients with T2DM is unclear and requires
further investigation. Recent studies have
reported that SGLT2 inhibitors in pancreatic
alpha cells trigger glucagon secretion [16]. The
resulting hyperglucagonemia might contribute
to ketogenesis under conditions of low insulin
concentration. The osmotic diuresis induced by
SGLT2 inhibitors can lead to dehydration,
reduction in intravascular volume, and ortho-
static hypotension.
The reported frequency of volume deple-
tion-related events ranges between 1.2% and
1.5% [24, 29]. The risk of postural hypotension
and dehydration is higher among patients
receiving diuretics (2.2–2.7%) than those who
do not (0.9–1.0%) [4, 30]. This risk is particu-
larly increased when combined with thiazides
and loop diuretics as a result of their mecha-
nism of action, enhancing the removal of
sodium and water. Patients over the age of
75 years have shown an up to 4.4% increased
frequency of postural hypotension [20, 21, 31].
Gastrointestinal AEs, such as nausea, vomiting,
and diarrhea, are main AEs of incretin drugs
(DPP4 inhibitors and GLP-1 receptor agonists,
GLP1ra), and metformin [32–34]. While in most
cases these symptoms are intermittent and
insidious, in some cases they can lead to dehy-
dration and an added risk of SGLT2 ther-
apy-associated volume depletion.
SGLT2 inhibitors might also affect bone
metabolism given the increased number of
bone fractures reported in some clinical trials
[35]. Indeed, the FDA released a warning for the
use of canagliflozin for this regard in 2005
[36, 37]. Nevertheless, a recent meta-analysis of
38 randomized controlled trials (involving
30,384 patients, and a follow-up period between
24 and 160 weeks) has questioned the harmful
effect of SGLT2 inhibitors on bone fractures
[38]. A pooled analysis of 10 randomized trials
has also suggested that the risk of fractures with
canagliflozin might be caused by falls, poten-
tially related to volume depletion-related AEs
[39].
Furthermore, the FDA and EMA recently
warned about a potential increased risk of lower
limb amputation, mainly toes, in patients
receiving canagliflozin [40, 41]. This warning is
based on the interim analysis of the ongoing
Canagliflozin Cardiovascular Assessment Study
(CANVAS) clinical trial, in which the incidence
of lower limb amputation was 7, 5, and 3 cases
every 1000 patients with 100, 300 mg canagli-
flozin, and placebo, respectively. Further studies
are required to corroborate the implication of





SGLT2 inhibitors are effective at any stage of the
natural history of T2DM owing to their
insulin-independent mechanism of action. This
fact supports their use as add-on therapy to any
other antidiabetic agent, and as monotherapy
in patients who are intolerant to metformin.
However, the requirement of an adequate renal
function and the development of AEs may limit
their use. The patient profile that can most
advantageously benefit from the properties of
these drugs includes younger ages; estimated
glomerular filtration rate at least 60 mL/min/
1.73 m2 (renal function not impaired); estab-
lished cardiovascular disease, no frequent geni-
tourinary tract infections, overweight or obese;
or hypertension (moderate to high blood
pressure).
Adjustment of Concomitant Therapies
Lower doses of SGLT2 inhibitors are recom-
mended when initiating treatment. It is also
important to review concomitant therapies in
order to minimize the risk of AEs. In the case of
glucose-lowering therapies (insulin, sulfony-
lureas), the recommendation for patients with
HbA1c less than 8.5% (less than 69 mmol/mol)
is to reduce their daily insulin dose by 20%,
with special caution to avoid insulin withdrawal
to minimize the risk of euglycemic diabetic
ketoacidosis (Fig. 2) [28, 31, 37, 42, 43]. Sul-
fonylureas should be reduced or stopped when
initiating SGLT2 inhibitors. In contrast, main-
taining the insulin dose is recommended for
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patients with HbA1c greater than 8.5% (greater
than 69 mmol/mol). In both cases, it is recom-
mended that the patients self-monitor their
blood glucose and adjust their insulin dose
according to their glycemic control. Patients
receiving metformin or an incretin-based ther-
apy (DPP4 inhibitors, GLP1ra) should be espe-
cially monitored for the occurrence of
gastrointestinal AEs. In the presence of vomit-
ing or diarrhea, lowering the dose of met-
formin, DPP4 inhibitors/GLP1ra should be
considered and vigorous fluid intake ensured.
Ketonuria and/or ketonemia (preferred) moni-
toring is indicated in patients taking an SGLT2
inhibitor who present with symptoms sugges-
tive of diabetic ketoacidosis, such as abdominal
pain, nausea, vomiting, fatigue, and dyspnea
[28]. When the concomitant therapy is a
diuretic, recommendations include withdraw-
ing the agent, and reconsidering the treatment
according to the clinical situation, such as
congestive heart failure, peripheral edema, or
impaired renal function. In patients who are
elderly and hemodynamically unstable (defined
as the presence of atrial fibrillation, blood
pressure lability, prior syncope), or with blood
pressure under 140/80 mmHg, the recommen-
dation is to decrease the antihypertensive
treatment, and to review the treatment accord-
ing to weekly monitoring. In contrast, in
patients receiving antihypertensive treatment
with high blood pressure who are hemody-
namically stable, the recommendation is to
maintain the antihypertensive treatment, and
to review the treatment according to weekly
monitoring.
CONCLUSIONS
SGLT2 inhibitors are an attractive novel thera-
peutic option for the treatment of T2DM. They
block the reabsorption of filtered glucose,
mainly in proximal renal tubules, resulting in
increased urinary glucose excretion and correc-
tion of diabetes-related hyperglycemia. Beyond
improving glucose control, SGLT2 inhibitors
offer potential benefits by reducing body weight
and blood pressure. On the basis of the efficacy
demonstrated in clinical trials, SGLT2 inhibitors
are recommended as second- or third-line
agents for the management of patients with
T2DM. Beneficial effects on kidney disease pro-
gression, cardiovascular and all-cause mortality,
and hospitalization for heart failure have also
been demonstrated with one SGLT2 inhibitor
(empagliflozin). Potential AEs resulting from
their mechanism of action (hypoglycemia and
volume depletion-related events) make it
advisable to review concomitant therapies
when initiating with SGLT2 inhibitors.
Although the overall frequency of AEs is rela-
tively low among these patients, some individ-
ual characteristics (elderly, patients receiving
diuretics, previous orthostatic hypotension,
blood pressure lability, or prior syncope) may
increase the risk of developing them.
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